Literature DB >> 12874454

Milder presentation of recessive polycystic kidney disease requires presence of amino acid substitution mutations.

Laszlo Furu1, Luiz F Onuchic, Ali Gharavi, Xiaoying Hou, Ernie L Esquivel, Yasuyuki Nagasawa, Carsten Bergmann, Jan Senderek, Ellis Avner, Klaus Zerres, Gregory G Germino, Lisa M Guay-Woodford, Stefan Somlo.   

Abstract

Autosomal recessive polycystic kidney disease (ARPKD; MIM 263200) is a hereditary and severe form of polycystic disease affecting the kidneys and biliary tract with an estimated incidence of 1 in 20,000 live births. The clinical spectrum is widely variable: up to 50% of affected neonates die shortly after birth, whereas others survive to adulthood. Mutations at a single locus, polycystic kidney and hepatic disease 1 (PKHD1), are responsible for all typical forms of ARPKD. Mutation detection was performed in PKHD1 by DHPLC in 85 affected, unrelated individuals. Seventy-four amplicons were amplified and analyzed from the PKHD1 genomic locus. Sequence variants were considered pathogenic when they were not observed in 160 control individuals (320 chromosomes). For purposes of genotype-phenotype comparisons, families were stratified by clinical presentation into two groups: the severe perinatal group, in which at least one affected child presented with perinatal disease and neonatal demise, and the less severe, nonperinatal group, in which none of the affected children died in the neonatal period. Forty-one mutations were found in 55 affected disease chromosomes; 32 of these mutations have not been reported previously. Mutations were distributed throughout the portions of gene encoding the predicted extracellular portion of the protein product. The most commonly encountered mutation, T36M, was found in 8 of 55 disease chromosomes. Amino acid substitutions were found to be more commonly associated with a nonlethal presentation, whereas chain terminating mutations were more commonly associated with neonatal demise (chi(2) = 11.54, P = 0.003). All patients who survive the neonatal period have at least one amino acid substitution mutation, suggesting that such substitutions produce milder disease through production of partially functional protein products. The nature of the germline mutations in ARPKD plays a significant role in determining clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12874454     DOI: 10.1097/01.asn.0000078805.87038.05

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  43 in total

1.  Comprehensive genetic testing in children with a clinical diagnosis of ARPKD identifies phenocopies.

Authors:  Tamás Szabó; Petronella Orosz; Eszter Balogh; Eszter Jávorszky; István Máttyus; Csaba Bereczki; Zoltán Maróti; Tibor Kalmár; Attila J Szabó; George Reusz; Ildikó Várkonyi; Erzsébet Marián; Éva Gombos; Orsolya Orosz; László Madar; György Balla; János Kappelmayer; Kálmán Tory; István Balogh
Journal:  Pediatr Nephrol       Date:  2018-06-28       Impact factor: 3.714

Review 2.  Ciliary dysfunction in polycystic kidney disease: an emerging model with polarizing potential.

Authors:  Robert J Kolb; Surya M Nauli
Journal:  Front Biosci       Date:  2008-05-01

Review 3.  An approach to cystic kidney diseases: the clinician's view.

Authors:  Christine E Kurschat; Roman-Ulrich Müller; Mareike Franke; David Maintz; Bernhard Schermer; Thomas Benzing
Journal:  Nat Rev Nephrol       Date:  2014-09-30       Impact factor: 28.314

4.  Posterior reversible encephalopathy syndrome in a uremic patient with autosomal recessive polycystic kidney disease.

Authors:  Tadashi Yoshida; Ken Hiratsuka; Maho Yamashita; Ayumi Matsui; Matsuhiko Hayashi
Journal:  CEN Case Rep       Date:  2015-04-01

5.  Functional analysis of PKHD1 splicing in autosomal recessive polycystic kidney disease.

Authors:  Carsten Bergmann; Valeska Frank; Fabian Küpper; Christa Schmidt; Jan Senderek; Klaus Zerres
Journal:  J Hum Genet       Date:  2006-08-03       Impact factor: 3.172

6.  Clinical characteristics and mutation analysis of three Chinese children with autosomal recessive polycystic kidney disease.

Authors:  Shu-Ping Liu; Jie Ding; Fang Wang; Yan-Qin Zhang; Jin-Tang Ye
Journal:  World J Pediatr       Date:  2014-08-15       Impact factor: 2.764

7.  A novel model of autosomal recessive polycystic kidney questions the role of the fibrocystin C-terminus in disease mechanism.

Authors:  Patricia Outeda; Luis Menezes; Erum A Hartung; Stacey Bridges; Fang Zhou; Xianjun Zhu; Hangxue Xu; Qiong Huang; Qin Yao; Feng Qian; Gregory G Germino; Terry Watnick
Journal:  Kidney Int       Date:  2017-07-18       Impact factor: 10.612

8.  Genetic interaction studies link autosomal dominant and recessive polycystic kidney disease in a common pathway.

Authors:  Miguel A Garcia-Gonzalez; Luis F Menezes; Klaus B Piontek; Junya Kaimori; David L Huso; Terry Watnick; Luiz F Onuchic; Lisa M Guay-Woodford; Gregory G Germino
Journal:  Hum Mol Genet       Date:  2007-06-16       Impact factor: 6.150

9.  Polyductin undergoes notch-like processing and regulated release from primary cilia.

Authors:  Jun-ya Kaimori; Yasuyuki Nagasawa; Luis F Menezes; Miguel A Garcia-Gonzalez; Jie Deng; Enyu Imai; Luiz F Onuchic; Lisa M Guay-Woodford; Gregory G Germino
Journal:  Hum Mol Genet       Date:  2007-04-15       Impact factor: 6.150

10.  Biliary and pancreatic dysgenesis in mice harboring a mutation in Pkhd1.

Authors:  Anna-Rachel Gallagher; Ernie L Esquivel; Tiffany S Briere; Xin Tian; Michihiro Mitobe; Luis F Menezes; Glen S Markowitz; Dhanpat Jain; Luiz F Onuchic; Stefan Somlo
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.